MCLA-129 (Not yet branded)

Other Medications

Experimental

Not available IV 3 Clinical Trials

EGFR c-MET

Description

MCLA-129 is a human bispecific monoclonal antibody that simultaneously targets both EGFR and c-MET receptors in solid tumors including colorectal cancer. This dual-targeting approach is designed to block two key growth pathways that are frequently overexpressed or mutated in colorectal cancer. The bispecific antibody format allows for enhanced tumor selectivity by requiring both target receptors to be present for optimal binding and activity.

Mechanism of Action

MCLA-129 binds to both epidermal growth factor receptor (EGFR) and c-MET receptor tyrosine kinase, blocking downstream signaling pathways that promote cancer cell proliferation, survival, and metastasis. By simultaneously inhibiting both pathways, the antibody aims to overcome resistance mechanisms that can develop when targeting either receptor alone.

Molecular Targets

EGFR c-MET

Side Effects

Skin rash Diarrhea Fatigue Nausea Decreased appetite Infusion reactions Hypomagnesemia Peripheral edema

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT07448116 Phase 1

Recruiting

Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors.

China

NCT04930432 Phase 1

Recruiting

Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors

China

NCT04868877 Phase 1

Active, not recruiting

Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

United States, Belgium, France, Germany, Italy, Netherlands, Singapore, South Ko

Quick Info

Brand Name	Not yet branded
Category	Other Medications
Status	Experimental
EMA Status	Experimental
Spain Access	Not available
Administration	IV
Clinical Trials	3

View Clinical Trials Back to Drug Glossary

Related Medications

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.